These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 10716315

  • 1. 111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR.
    Reilly RM, Kiarash R, Cameron RG, Porlier N, Sandhu J, Hill RP, Vallis K, Hendler A, Gariépy J.
    J Nucl Med; 2000 Mar; 41(3):429-38. PubMed ID: 10716315
    [Abstract] [Full Text] [Related]

  • 2. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
    Chen P, Cameron R, Wang J, Vallis KA, Reilly RM.
    J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194
    [Abstract] [Full Text] [Related]

  • 3. Multifunctional block copolymer micelles for the delivery of 111In to EGFR-positive breast cancer cells for targeted Auger electron radiotherapy.
    Fonge H, Lee H, Reilly RM, Allen C.
    Mol Pharm; 2010 Feb 01; 7(1):177-86. PubMed ID: 19924993
    [Abstract] [Full Text] [Related]

  • 4. A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting 111In to EGFR-positive breast cancer cells and tumor xenografts in athymic mice.
    Panosa C, Fonge H, Ferrer-Batallé M, Menéndez JA, Massaguer A, De Llorens R, Reilly RM.
    Nucl Med Biol; 2015 Dec 01; 42(12):931-8. PubMed ID: 26385534
    [Abstract] [Full Text] [Related]

  • 5. A kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111In for radiotherapeutic applications.
    Reilly RM, Scollard DA, Wang J, Mondal H, Chen P, Henderson LA, Bowen BM, Vallis KA.
    J Nucl Med; 2004 Apr 01; 45(4):701-8. PubMed ID: 15073268
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Relationship between induction of phosphorylated H2AX and survival in breast cancer cells exposed to 111In-DTPA-hEGF.
    Cai Z, Chen Z, Bailey KE, Scollard DA, Reilly RM, Vallis KA.
    J Nucl Med; 2008 Aug 01; 49(8):1353-61. PubMed ID: 18632822
    [Abstract] [Full Text] [Related]

  • 8. Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor.
    Bailey KE, Costantini DL, Cai Z, Scollard DA, Chen Z, Reilly RM, Vallis KA.
    J Nucl Med; 2007 Sep 01; 48(9):1562-70. PubMed ID: 17704253
    [Abstract] [Full Text] [Related]

  • 9. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
    Razumienko EJ, Chen JC, Cai Z, Chan C, Reilly RM.
    J Nucl Med; 2016 Mar 01; 57(3):444-52. PubMed ID: 26429962
    [Abstract] [Full Text] [Related]

  • 10. ¹¹¹In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer.
    Fasih A, Fonge H, Cai Z, Leyton JV, Tikhomirov I, Done SJ, Reilly RM.
    Breast Cancer Res Treat; 2012 Aug 01; 135(1):189-200. PubMed ID: 22736376
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts.
    Ke S, Wen X, Gurfinkel M, Charnsangavej C, Wallace S, Sevick-Muraca EM, Li C.
    Cancer Res; 2003 Nov 15; 63(22):7870-5. PubMed ID: 14633715
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. In vivo toxicity, pharmacokinetics, and anticancer activity of Genistein linked to recombinant human epidermal growth factor.
    Uckun FM, Narla RK, Zeren T, Yanishevski Y, Myers DE, Waurzyniak B, Ek O, Schneider E, Messinger Y, Chelstrom LM, Gunther R, Evans W.
    Clin Cancer Res; 1998 May 15; 4(5):1125-34. PubMed ID: 9607569
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. 111In- or 99mTc-labeled recombinant VEGF bioconjugates: in vitro evaluation of their cytotoxicity on porcine aortic endothelial cells overexpressing Flt-1 receptors.
    Chan C, Cai Z, Su R, Reilly RM.
    Nucl Med Biol; 2010 Feb 15; 37(2):105-15. PubMed ID: 20152709
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Characterization of epidermal growth factor receptor and action on human breast cancer cells in culture.
    Fitzpatrick SL, LaChance MP, Schultz GS.
    Cancer Res; 1984 Aug 15; 44(8):3442-7. PubMed ID: 6331647
    [Abstract] [Full Text] [Related]

  • 20. Mechanisms of the growth-inhibitory effect of the RNase-EGF fused protein against EGFR-overexpressing cells.
    Hoshimoto S, Ueda M, Jinno H, Kitajima M, Futami J, Seno M.
    Anticancer Res; 2006 Aug 15; 26(2A):857-63. PubMed ID: 16619480
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.